{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:53:58Z","timestamp":1781654038222,"version":"3.54.5"},"reference-count":46,"publisher":"Norwegian Medical Association","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"published-print":{"date-parts":[[2013,10,15]]},"DOI":"10.4045\/tidsskr.13.0608","type":"journal-article","created":{"date-parts":[[2013,10,16]],"date-time":"2013-10-16T04:53:43Z","timestamp":1381899223000},"page":"2057-61","source":"Crossref","is-referenced-by-count":0,"title":["Neuromyelitis optica"],"prefix":"10.4045","volume":"133","author":[{"given":"Silje Agnethe Stokke","family":"Kvistad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stig","family":"Wergeland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ivind","family":"Torkildsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell-Morten","family":"Myhr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian A.","family":"Vedeler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"Jarius S, Wildemann B. The history of neuromyelitis optica. J Neuroinflammation 2013; 10: 8.","DOI":"10.1186\/1742-2094-10-8"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Lennon VA, Wingerchuk DM, Kryzer TJ et al. A\u00a0serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106\u2009\u2013\u200912.","DOI":"10.1016\/S0140-6736(04)17551-X"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Kim W, Kim SH, Kim HJ. New insights into neuromyelitis optica. J Clin Neurol 2011; 7: 115\u2009\u2013\u200927.","DOI":"10.3988\/jcn.2011.7.3.115"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol 2012; 11: 535\u2009\u2013\u200944.","DOI":"10.1016\/S1474-4422(12)70133-3"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Asgari N, Lillevang ST, Skejoe HP et al. A population-based study of neuromyelitis optica in Caucasians. Neurology 2011; 76: 1589\u2009\u2013\u200995.","DOI":"10.1212\/WNL.0b013e3182190f74"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Bukhari W, Barnett MH, Prain K et al. Molecular pathogenesis of neuromyelitis optica. Int J Mol Sci 2012; 13: 12970\u2009\u2013\u200993.","DOI":"10.3390\/ijms131012970"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Oh J, Levy M. Neuromyelitis optica: an antibody-mediated disorder of the central nervous system. Neurol Res Int 2012. E-publisert 29.1.2012.","DOI":"10.1155\/2012\/460825"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Wingerchuk DM, Lennon VA, Lucchinetti CF et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805\u2009\u2013\u200915.","DOI":"10.1016\/S1474-4422(07)70216-8"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Wingerchuk DM, Hogancamp WF, O\u2019Brien PC et al. The clinical course of neuromyelitis optica (Devic\u2019s syndrome). Neurology 1999; 53: 1107\u2009\u2013\u200914.","DOI":"10.1212\/WNL.53.5.1107"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Ghezzi A, Bergamaschi R, Martinelli V et al. Clinical characteristics, course and prognosis of relapsing Devic\u2019s Neuromyelitis Optica. J Neurol 2004; 251: 47\u2009\u2013\u200952.","DOI":"10.1007\/s00415-004-0271-0"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Jarius S, Ruprecht K, Wildemann B et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation 2012; 9: 14.","DOI":"10.1186\/1742-2094-9-14"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Sellner J, Boggild M, Clanet M et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010; 17: 1019\u2009\u2013\u200932.","DOI":"10.1111\/j.1468-1331.2010.03066.x"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Takano R, Misu T, Takahashi T et al. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 2010; 75: 208\u2009\u2013\u200916.","DOI":"10.1212\/WNL.0b013e3181e2414b"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Miyazawa I, Nakashima I, Petzold A et al. High CSF neurofilament heavy chain levels in neuromyelitis optica. Neurology 2007; 68: 865\u2009\u2013\u20097.","DOI":"10.1212\/01.wnl.0000256820.26489.17"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Jacob A, McKeon A, Nakashima I et al. Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry 2013; 84: 922\u2009\u2013\u200930.","DOI":"10.1136\/jnnp-2012-302310"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Pittock SJ, Lennon VA, Krecke K et al. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006; 63: 390\u2009\u2013\u20096.","DOI":"10.1001\/archneur.63.3.390"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Hinson SR, McKeon A, Lennon VA. Neurological autoimmunity targeting aquaporin-4. Neuroscience 2010; 168: 1009\u2009\u2013\u200918.","DOI":"10.1016\/j.neuroscience.2009.08.032"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Barnett MH, Sutton I. Neuromyelitis optica: not a\u00a0multiple sclerosis variant. Curr Opin Neurol 2012; 25: 215\u2009\u2013\u200920.","DOI":"10.1097\/WCO.0b013e3283533a3f"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Wingerchuk DM, Lennon VA, Pittock SJ et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485\u2009\u2013\u20099.","DOI":"10.1212\/01.wnl.0000216139.44259.74"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Wingerchuk DM. Neuromyelitis optica. Int MS J\u00a02006; 13: 42\u2009\u2013\u200950.","DOI":"10.1097\/01.nrl.0000250927.21903.f8"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Miller DH, Weinshenker BG, Filippi M et al. Differential diagnosis of suspected multiple sclerosis: a\u00a0consensus approach. Mult Scler 2008; 14: 1157\u2009\u2013\u200974.","DOI":"10.1177\/1352458508096878"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"O\u2019Riordan JI, Gallagher HL, Thompson AJ et al. Clinical, CSF, and MRI findings in Devic\u2019s neuromyelitis optica. J Neurol Neurosurg Psychiatry 1996; 60: 382\u2009\u2013\u20097.","DOI":"10.1136\/jnnp.60.4.382"},{"key":"ref=23","unstructured":"Lycke J, Malmestr\u00f6m C. Neuromyelitis optica \u2013 viktig differentialdiagnos till MS. Tidigt insatt behandling avg\u00f6rande for prognosen. L\u00e4kartidningen 2010; 107: 3212\u2009\u2013\u20095."},{"key":"ref=24","unstructured":"Waters P, Vincent A. Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays. Int MS J 2008; 15: 99\u2009\u2013\u2009105."},{"key":"ref=25","doi-asserted-by":"crossref","unstructured":"Thornton IL, Rizzo JF, Cestari DM. Neuromyelitis optica: a review. Semin Ophthalmol 2011; 26: 337\u2009\u2013\u200941.","DOI":"10.3109\/08820538.2011.588667"},{"key":"ref=26","unstructured":"Nevro-Nel. Norsk nevrologisk forenings prosedyrer. http:\/\/nevro.legehandboka.no\/ (23.7.2013)."},{"key":"ref=27","doi-asserted-by":"crossref","unstructured":"Matiello M, Kim HJ, Kim W et al. Familial neuromyelitis optica. Neurology 2010; 75: 310\u2009\u2013\u20095.","DOI":"10.1212\/WNL.0b013e3181ea9f15"},{"key":"ref=28","doi-asserted-by":"crossref","unstructured":"Lucchinetti CF, Mandler RN, McGavern D et al. A\u00a0role for humoral mechanisms in the pathogenesis of Devic\u2019s neuromyelitis optica. Brain 2002; 125: 1450\u2009\u2013\u200961.","DOI":"10.1093\/brain\/awf151"},{"key":"ref=29","doi-asserted-by":"crossref","unstructured":"Nagelhus EA, Mathiisen TM, Ottersen OP. Aquaporin-4 in the central nervous system: cellular and subcellular distribution and coexpression with KIR4.1. Neuroscience 2004; 129: 905\u2009\u2013\u200913.","DOI":"10.1016\/j.neuroscience.2004.08.053"},{"key":"ref=30","doi-asserted-by":"crossref","unstructured":"Hinson SR, Pittock SJ, Lucchinetti CF et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007; 69: 2221\u2009\u2013\u200931.","DOI":"10.1212\/01.WNL.0000289761.64862.ce"},{"key":"ref=31","doi-asserted-by":"crossref","unstructured":"Llufriu S, Castillo J, Blanco Y et al. Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months. Neurology 2009; 73: 949\u2009\u2013\u200953.","DOI":"10.1212\/WNL.0b013e3181b879be"},{"key":"ref=32","doi-asserted-by":"crossref","unstructured":"Watanabe S, Nakashima I, Misu T et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007; 13: 128\u2009\u2013\u200932.","DOI":"10.1177\/1352458506071174"},{"key":"ref=33","doi-asserted-by":"crossref","unstructured":"Palace J, Leite MI, Jacob A. A practical guide to the treatment of neuromyelitis optica. Pract Neurol 2012; 12: 209\u2009\u2013\u200914.","DOI":"10.1136\/practneurol-2012-000237"},{"key":"ref=34","doi-asserted-by":"crossref","unstructured":"Mandler RN, Ahmed W, Dencoff JE. Devic\u2019s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998; 51: 1219\u2009\u2013\u200920.","DOI":"10.1212\/WNL.51.4.1219"},{"key":"ref=35","doi-asserted-by":"crossref","unstructured":"Bichuetti DB, Lobato de Oliveira EM, Oliveira DM et al. Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol 2010; 67: 1131\u2009\u2013\u20096.","DOI":"10.1001\/archneurol.2010.203"},{"key":"ref=36","doi-asserted-by":"crossref","unstructured":"Bedi GS, Brown AD, Delgado SR et al. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 2011; 17: 1225\u2009\u2013\u200930.","DOI":"10.1177\/1352458511404586"},{"key":"ref=37","doi-asserted-by":"crossref","unstructured":"Pellkofer HL, Krumbholz M, Berthele A et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 2011; 76: 1310\u2009\u2013\u20095.","DOI":"10.1212\/WNL.0b013e3182152881"},{"key":"ref=38","doi-asserted-by":"crossref","unstructured":"Carroll WM, Fujihara K. Neuromyelitis optica. Curr Treat Options Neurol 2010; 12: 244\u2009\u2013\u200955.","DOI":"10.1007\/s11940-010-0071-z"},{"key":"ref=39","doi-asserted-by":"crossref","unstructured":"Sato D, Callegaro D, Lana-Peixoto MA et al. Treatment of neuromyelitis optica: an evidence based review. Arq Neuropsiquiatr 2012; 70: 59\u2009\u2013\u200966.","DOI":"10.1590\/S0004-282X2012000100012"},{"key":"ref=40","doi-asserted-by":"crossref","unstructured":"Pittock SJ, Lennon VA, McKeon A et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013; 12: 554\u2009\u2013\u200962.","DOI":"10.1016\/S1474-4422(13)70076-0"},{"key":"ref=41","doi-asserted-by":"crossref","unstructured":"Papeix C, Vidal JS, de Seze J et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 2007; 13: 256\u2009\u2013\u20099.","DOI":"10.1177\/1352458506070732"},{"key":"ref=42","doi-asserted-by":"crossref","unstructured":"Barnett MH, Prineas JW, Buckland ME et al. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler 2012; 18: 108\u2009\u2013\u200912.","DOI":"10.1177\/1352458511421185"},{"key":"ref=43","doi-asserted-by":"crossref","unstructured":"Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 2012; 18: 113\u2009\u2013\u20095.","DOI":"10.1177\/1352458511431973"},{"key":"ref=44","doi-asserted-by":"crossref","unstructured":"Kleiter I, Hellwig K, Berthele A et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012; 69: 239\u2009\u2013\u200945.","DOI":"10.1001\/archneurol.2011.216"},{"key":"ref=45","doi-asserted-by":"crossref","unstructured":"Wang KC, Lee CL, Chen SY et al. Glatiramer acetate could be a hypothetical therapeutic agent for neuromyelitis optica. Med Hypotheses 2011; 76: 820\u2009\u2013\u20092.","DOI":"10.1016\/j.mehy.2011.02.027"},{"key":"ref=46","doi-asserted-by":"crossref","unstructured":"Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 2003; 60: 848\u2009\u2013\u200953.","DOI":"10.1212\/01.WNL.0000049912.02954.2C"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":[],"language":"no","deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:10:41Z","timestamp":1781651441000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2013\/10\/oversiktsartikkel\/neuromyelitis-optica"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,15]]},"references-count":46,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2013,10,15]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.13.0608","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,15]]}}}